The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2024 | Treatment of anemia in LR-MDS: luspatercept and imetelstat
Anand Patel, MD, The University of Chicago Medicine, Chicago, IL, discusses the COMMANDS (NCT03682536) and IMerge (NCT02598661) studies, which explored luspatercept and imetelstat respectively, for the treatment of anemia in lower-risk myelodysplastic syndromes (LR-MDS). Dr Patel also mentions open questions about these therapies, such as how they should be sequenced. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
